Thank you, Chair, and thank you, witnesses, for your great testimony.
I'd like to ask you about priorities.
I'll start with you, Dr. Nickerson. You mentioned that your recommendation number one is to identify priorities. That sounds great, but then I started to think that it begs the question. When I think about it a bit further, I think that we already do establish priorities. There's limited funding and somebody makes choices about where that funding goes, whether it's government funding or an R and D fund in a corporation.
Here's my question to you, sir: How should we set those priorities? We can't necessarily do it on a population basis, because if you look at it in terms of the most people who have this disease, you leave the rare diseases orphaned. It's a tough nut to crack, I think. How would you suggest that we set those priorities?